Servier and Nymirum, a pioneer in RNA-targeted small molecules, have entered into a collaboration to identify and develop RNA-modulatory drugs for the treatment of neurological diseases.
Under the collaboration agreement, the North Carolina-based biotech will leverage its proprietary DART Platform (Dynamic Atomic-Resolution RNA Targeting) to discover novel small molecule therapeutics for multiple neurological targets. Servier is responsible for joint preclinical development and has the right to pursue further development on the current targets as well as expand the scope of the collaboration.
“This new collaboration is the opportunity to progress innovative RNA-targeted approaches towards clinical assessment in patients with very limited or absent treatment options,” stated Ross Jeggo, Global Head of Neuroscience and Immuno-Inflammation Therapeutic Area at Servier.
Servier has been involved in neuroscience for several decades and makes therapeutic solutions available to patients suffering from depression. The research and development teams work on both neurodegenerative diseases such as Parkinson and neurodevelopmental disorders such as autism, to provide innovative therapeutic solutions.